| Molecule | Cat. No. | Product Name | Art | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| IL-13 R alpha 2 | HOT IL2-H5256 | Human IL-13 R alpha 2 Protein, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 200ug | ||
| IL-13 R alpha 2 | HOTAvitag IL2-H82E6 | Biotinylated Human IL-13 R alpha 2 Protein, His,Avitag™ (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $370.00 25ug | ||
| IL-13 R alpha 2 | Human IL-13 R alpha 2 Protein, His Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $350.00 100ug | |||
| IL-13 R alpha 2 | HOT IL2-HF2H3 | FITC-Labeled Human IL-13 R alpha 2 Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $330.00 25ug | ||
| IL-13 R alpha 2 | Canine IL-13 R alpha 2 Protein, His Tag (MALS verified) | Canine | HEK293 | ![]() | MALSSDS-PAGE | $310.00 100ug | |||
| IL-13 R alpha 2 | Mouse IL-13 R alpha 2 Protein, Fc Tag (MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $310.00 100ug | |||
| IL-13 R alpha 2 | Mouse IL-13 R alpha 2 Protein, His Tag (MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $310.00 100ug | |||
| IL-13 R alpha 2 | Rhesus macaque IL-13 R alpha 2 Protein, His Tag | Rhesus macaque | HEK293 | ![]() | SDS-PAGE | $310.00 100ug |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| MB-101 (Mustang Bio) | MB-101 | Phase 1 Clinical | City Of Hope National Medical Center, Mustang Bio Inc | Brain Neoplasms; CNS Embryonal Tumor; Glioblastoma; Glioma | Details |
| IL13Ralpha2 CAR-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Adenocarcinoma of Lung; Adenoma, Islet Cell; Adrenocortical Carcinoma; Breast Neoplasms; Ependymoma; Glioblastoma; Medulloblastoma; Melanoma; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Thyroid Neoplasms; Uveal melanoma | Details | |
| E-Sync T Cell Therapy (University of California/National Cancer Institute/California Institute for Regenerative Medicine) | Phase 1 Clinical | University Of California San Francisco | Glioblastoma | Details | |
| EPC-003 | EPC-003 | Phase 1 Clinical | Elpis BioPharmaceuticals Corp | Glioblastoma; Multiple Myeloma | Details |
| IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody therapy (Emergency General Hospital) | Phase 1 Clinical | Emergency General Hospital, Department of Neurosurgery | Glioma | Details | |
| IL13Rα2 targeted CAR-T cell(Yooyoung) | YYB-103; CLM-103 | Phase 1 Clinical | YooYoung Pharmaceutical Co Ltd | Amyotrophic Lateral Sclerosis; Glioma | Details |
| Autologous TGF-betaR2KO/IL13R-alpha2-CAR T cells Therapy(City of Hope Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Astrocytoma; Glioblastoma | Details | |
| MT-026 | MT-026 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Glioma | Details |
| SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |